Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22113418 | 0.79 | TSHR (0.50) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL16426472 | 0.77 | TSHR (0.53) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL24126973 | 0.75 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL9965906 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ATSHRNPSR1 | |
| SCHEMBL17001650 | 0.74 | ALOX15 (0.45) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| Hydrochloric Acid SCHEMBL22528409 | 0.73 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATSHRNPSR1 | |
| SCHEMBL12435470 | 0.72 | MEN1 (0.40) | ALDH1A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL12436842 | 0.72 | MEN1 (0.38) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL12436080 | 0.72 | MEN1 (0.38) | ALDH1A1MEN1KMT2ATSHRLMNA | |
| SCHEMBL9963184 | 0.69 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | ALDH1A1 748/4885MEN1 4367/4885KMT2A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.